

ITALY – OCTOBER 2022








Status of Cardiovascular Disease (CVD) and Non-communicable diseases (NCD)

Country Demographics

World Bank Classification
High income




Life expectancy at birth (in years):




Percentage of adults (age-standardized estimate) who are insufficiently active (**less than 150 minutes** of moderate intensity physical activity per week, or less than 75 minutes of vigorous-intensity physical activity per week):




Percentage of adults who are overweight (body mass index (BMI) of 25 kg/m² or higher):



Percentage of adolescents (ages 11-17) who are insufficiently active (**less than 60 minutes** of moderate- to vigorous intensity physical activity daily):



Prevalence of diabetes in adults (ages 20-79):





ITALY

Health System Capacity



39.5

Number of physicians (per 10,000 population)



66

Number of nurses (per 10,000 population)



31.9

Number of hospital beds (per 10,000 population)

KEY:

No data



Not in place



In process/ partially implemented



In place



Essential Medicines and Interventions

Following essential medicines generally available in primary care facilities in the public health sector:

ACE inhibitors:		Metformin:	
Aspirin:		Insulin:	
Beta blockers:		Warfarin:	
Statins:		Clopidogrel:	

Clinical Practice and Guidelines

Locally-relevant (national or subnational level):

Clinical tool to assess CVD risk:	
CVD prevention (within the last 5 years):	
Treatment of tobacco dependence:	
Detection and management of Atrial Fibrillation:	

Cardiovascular Disease Governance

A National strategy or plan that addresses:

- CVDs and their risk factors specifically:
- NCDs and their risk factors:
- A national tobacco control plan:
- A national multisectoral coordination mechanism for tobacco control:
- A national surveillance system that includes CVDs and their risk factors:
- Legislation that mandates essential CVD medicines at affordable prices:
- Policies that ensure screening of individuals at high risk of CVDs:

Stakeholder action

- NGO advocacy for CVD policies and programmes:
- Active involvement of patients' organizations in advocacy for CVD prevention and management:
- Involvement of civil society in the development and implementation of a national CVD prevention and control plan:
- Specific activities by cardiology professional associations aimed at 25% reduction in premature CVD mortality by 2025:
- Hypertension screening by businesses at workplaces: